Compare Aurora Cannabis Inc (ACB) vs Arqit Quantum Inc (ARQQ) Price & Performance

Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.

ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.

ARQQ trades at $22.90, up 6.66% with bullish technical signals from moving averages and ADX indicators. The company shows explosive revenue growth (829% YoY in H1 FY26) but remains deeply unprofitable with a -4,508% net margin and negative cash flow from operations. Recent news highlights quantum-safe encryption partnerships and government contract wins, though financial sustainability concerns persist.

The stock presents high-risk speculation on quantum security adoption versus fundamental weaknesses. Upside depends on commercializing technology into sustainable profits, while downside risks include cash burn and competitive threats. Analyst consensus is split 50/50 buy/hold with no institutional conviction evident in current financial metrics.